Kezar rejects Concentra bid that ‘substantially undervalues’ the biotech
Kezar Life Sciences has become the latest biotech to decide that it could do better than a buyout offer from Concentra Biosciences.
All Posts in "Editor"
Sage lays off half of R&D team, shakes up C-suite again
Sage Therapeutics’ latest attempt to shrink its pipeline and workforce will see a third of the biotech’s employees heading for the exits along with a swath of the company’s leadership.
Novartis pays China’s Baiyu $70M upfront, with $1.1B chaser, for small molecule cancer candidate
Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. The deal, which features $1.1 billion in milestones, covers the global rights to a small molecule discovered by a Chinese biotech that has built a business around botanical drugs.
Sanofi returns to Orano with €300M for radioligand ‘pioneer’ project
Weeks after penning a $110 million upfront deal with Orano Med for the global rights to a neuroendocrine tumor treatment, Sanofi has returned with 300 million euros ($326 million) to set up a more permanent radioligand project.
J&J jettisons several programs, ends seltorexant work in Alzheimer’s disease
Johnson & Johnson is jettisoning several programs, with three of the culls taking place in the neuroscience field.
Chinese insulin maker says its GLP-1 beat Ozempic at lowering blood sugar, body weight in phase 2
Chinese insulin maker Gan & Lee Pharmaceuticals is wading into the obesity world with an injectable GLP-1 agonist that beat Novo Nordisk’s Ozempic (semaglutide) at lowering glycated hemoglobin (HbA1c) and body weight in a phase 2 trial in patients with type 2 diabetes, the company announced in an Oct. 15 release.
Ceribell CEO Jane Chao explains why now was the time for its upsized IPO
Ceribell rang in a $180.3 million IPO last week, with its public debut on the Nasdaq coming in well above its first pricing goal of about $101 million and its stock price trading up about 47% following the launch.
New cell therapy biotech emerges with $17M, thymus-targeting therapies
Cell therapy biotech Tolerance Bio has unveiled with $17.2 million and a mission of targeting immune diseases by stretching and saving the function of a key organ.
Notable Labs files for bankruptcy, ending ambitions for Boehringer cancer drug
Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for bankruptcy.
Topas says celiac candidate shines in phase 2a but keeps data under wraps for now
Topas Therapeutics has hailed a win for its immune-tolerance platform, reporting positive phase 2a data on its celiac disease candidate without sharing numbers to validate its upbeat outlook.
RFK Jr, noted vaccine sceptic, backs measles jab amid deadly US outbreak
Sad Case of The Youngest Person Ever Diagnosed With Alzheimer’s
Cell connects: Breaking barriers in stem cell communication through mRNA transfer
Fed-Batch Data Inadequate for Continuous Cultivation in Certain Systems
Pioneering work generates feline embryonic stem cells in boon for cats
Alzheimer’s Disease Could Be Influenced by HSV-1 Infections via Jumping Genes
RFK Jr. canceled flu vaccine meetings. What does that mean for fall shots?
What to know about the dangers of expired medications
Conservation focusing on birds of a feather may have mixed results
Cell connects: Breaking barriers in stem cell communication through mRNA transfer